Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Holstebro Hospital |
---|---|
Information provided by: | Holstebro Hospital |
ClinicalTrials.gov Identifier: | NCT00281710 |
We wanted to test the hypotheses that methylprednisolone up regulates u-AQP-2 in fasting healthy humans
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: Methylprednisolone |
Phase IV |
Study Type: | Interventional |
Study Design: | Randomized, Single Blind, Placebo Control, Crossover Assignment |
Official Title: | Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Denmark | |
Department of Medicine, Holstebro Hospital | |
Holstebro, Denmark |
Study Chair: | Erling B Pedersen, Professor | Holstebro Hospital, 7500 Holstebro, Denmark |
Principal Investigator: | Thomas G Knudsen, MD | Holstebro Sygehus |
Study ID Numbers: | MED.RES.HOS.2005.02.TGK |
Study First Received: | January 23, 2006 |
Last Updated: | May 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00281710 |
Health Authority: | Denmark: Ethics Committee |
AQP-2 Methylprednisolone Urinary concentrating ability |
Methylprednisolone Prednisolone Methylprednisolone acetate |
Prednisolone acetate Healthy Methylprednisolone Hemisuccinate |
Anti-Inflammatory Agents Antineoplastic Agents, Hormonal Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Gastrointestinal Agents Antiemetics Neuroprotective Agents |
Protective Agents Glucocorticoids Hormones Pharmacologic Actions Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Central Nervous System Agents |